Singapore, Aug. 12 -- Japan-based Solasia Pharma has entered into a licensing agreement with Firebird Biologics (headquartered in Singapore) granting exclusive rights for the sales and distribution of the anti-tumour drug DARVIAS (generic name: darinaparsin) and the medical device Episil (intended for the management and relief of oral pain caused by chemotherapy- or radiation therapy- induced oral mucositis) across 19 countries in Southeast Asia, Oceania, Middle East, and Africa.

Published by HT Digital Content Services with permission from BioSpectrum Asia....